Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9838107 | 1.00 | MEN1 (0.53) | MEN1KMT2AALDH1A1HPGDSIRT2 | |
| SCHEMBL22271575 | 1.00 | MEN1 (0.53) | MEN1KMT2AALDH1A1HPGDSIRT2 | |
| SCHEMBL5017052 | 1.00 | MEN1 (0.53) | MEN1KMT2AALDH1A1HPGDSIRT2 | |
| SCHEMBL8162401 | 1.00 | MEN1 (0.53) | MEN1KMT2AALDH1A1HPGDSIRT2 | |
| SCHEMBL18729465 | 0.94 | FOLH1 (0.53) | — | |
| SCHEMBL17767808 | 0.94 | FOLH1 (0.53) | — | |
| SCHEMBL17832976 | 0.92 | KMT2A (0.64) | MEN1KMT2AALDH1A1HPGDSIRT2 | |
| SCHEMBL15931039 | 0.91 | SIRT2 (0.55) | MEN1KMT2AALDH1A1HPGDSIRT2 | |
| SCHEMBL28252935 | 0.89 | SIRT2 (0.51) | MEN1KMT2AALDH1A1HPGDSIRT2 | |
| SCHEMBL28252938 | 0.89 | SIRT2 (0.51) | MEN1KMT2AALDH1A1HPGDSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309336-B1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | BIOSOURCE PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1309336-A4 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | MICROLOGIX BIOTECH INC (CA) | 2005-01-05 | — | — | EP | disclosed |
| US-6737403-B2 | CULTURING MICROORGANISM STREPTOMYCES VIRIDOCHROMOGENES, SSP. KOMABENSIS (ATCC 29814) IN CULTURE MEDIUM, ISOLATING LASPARTOMYCIN, CLEAVING LIPOPHILIC FRAGMENT FROM LASPARTOMYCIN, THEREBY YIELDING LASPARTOMYCIN CORE PEPTIDE | MICROLOGIX BIOTECH INC. (CA) | 2004-05-18 | — | — | US | disclosed |
| EP-1309336-A1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | Micrologix Biotech, Inc. (CA) | 2003-05-14 | — | — | EP | disclosed |
| US-20020035063-A1 | Derivatives of laspartomycin and preparation and use thereof | BIOSOURCE PHARM, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002005838-A1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | INTRABIOTICS PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035063-A1 | Derivatives of laspartomycin and preparation and use thereof | VIP, LAS1L, PREP | MEN1 2026/4885KMT2A 4806/4885ALDH1A1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.